The aging population, obesity and diabetes are on the rise. The WHO estimates 630 million diabetic patients by 2030. These patients have a 25% probability of suffering from hard-to-heal wounds during their lifetime. These wounds are very care intensive and have high reoccurrence rates. The burden on healthcare systems around the globe is huge and the patients suffer from pain and immobility, which dramatically reduces their quality of life. Complications such as infections or tissue necrosis can lead to amputations.
Piomic develops a wearable medical device for the treatment of hard-to-heal wounds. Acceleration of wound healing processes reduces pain, the risk of wound infections and increases the quality of life in patients suffering from chronic wounds.
„We want to fundamentally change the way people heal.“ – Christopher Hertz
The startup from Zurich uses electromagnetic stimulation to increase the energy content of living cells. Supercharging the cells accelerates the healing process and improves clinical outcomes. In addition to that, certain frequencies can specifically target certain enzymatic processes.
Piomic’s technology is portable, easy-to-use, affordable and fits seamlessly into the workflow of healthcare professionals. The device is in compliance with market mega-trends for portability and patient self-management.
The company was founded by three friends, ETHZ biologists Christopher Hertz and Marc Augsburger and machine engineer Jari Kruth. CE-certification and EU market clearance under MDD & MDR regulations are expected by 2020.